News | September 11, 2013

MaineHealth Aims to Achieve American Society of Nuclear Cardiology Guidelines with UltraSPECT Technology

Healthcare system selects UltraSPECT nuclear medicine software for lowering dose and reducing exam time

UltraSPECT Xpress.Cardiac, UltraSPECT, nuclear imaging, gamma cameras

UltraSPECT Xpress.Cardiac

September 11, 2013 -- UltraSPECT announced that MaineHealth, a family of hospitals and medical centers throughout Maine, has selected the UltraSPECT Xpress.Cardiac and Xpress3.Cardiac solutions as part of the organization’s strategy for reducing nuclear medicine (NM) dose and complying with the American Society of Nuclear Cardiology (ASNC) final guidelines effective Jan. 1, 2014. Maine Medical Partners (MMP)MaineHealth Cardiology in South Portland is one of 10 facilities within MaineHealth that is installing the product, with others scheduled to continue roll out before the end of 2013. 

"Radiation exposure reduction is a global priority and is readily achievable today through a combination of practices that includes innovative software like that from UltraSPECT," says Mylan Cohen, M.D., medical director of noninvasive cardiology at Maine Medical Center and former ASNC president. "MaineHealth is proud to be a leader in meeting the American Society of Nuclear Cardiology dose-reduction recommendations as we continue to take steps to implement advanced methods to reduce radiation exposure related to cardiac imaging for patients under our care."

ASNC recommends that the nuclear cardiology community limit the total radiation exposure to patients undergoing SPECT/PET myocardial perfusion imaging (MPI) tests to an average of less than or equal to 9 mSv (millisieverts) in 50 percent of studies by 2014. Previously, the average was approximately 12 to 13 mSv for stress and rest imaging. 

MMP — MaineHealth Cardiology conducts nearly 2800 nuclear medicine studies each year. The goal for the facility is to reduce both radiation dose, as well as the length of time of each study. Using the company’s proprietary Wide Beam Reconstruction (WBR) algorithm, the solution enhances the performance of existing NM cameras, enabling a 50 percent reduction in standard radiopharmaceutical injected dose, reducing imaging scan time up to 50 percent for abbreviated exams and greater patient comfort, while maintaining the highest level of image quality. Further, the UltraSPECT Xpress3.Cardiac software is the only solution for lowering dose and shortening exam time that works with all manufacturers’ SPECT cameras to cost-effectively retrofit existing technology for optimal patient outcomes, something that is especially ideal for a large organization like MaineHealth.

The selection of UltraSPECT comes in part as a result of the agreement between UltraSPECT and radiopharmaceutical provider PharmaLogic, under which PharmaLogic is offering the WBR software as part of its patient-centered approach. Healthcare organizations can now streamline the acquisition of UltraSPECT’s software through PharmaLogic versus making a standard capital purchase directly from UltraSPECT.

For more information visit www.ultraspect.com

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...